Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

NCT02979977 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Cancers of the Head and Neck

Interventions

DRUG: cetuximab
DRUG: afatinib

Sponsor

Yale University

Collaborators

[object Object]
[object Object]